The crazy thing with the current regulations is the company would have been better off financially not ever doing the study. Since doctors can proscribe off-label, if they had not done the larger study they could have kept selling Avastin to breast cancer patients on the sly.<p>Avastin probably does work for some breast cancer patients if they have a cancer with the right mutations, but if the percentage is a small enough then the large study would not be able to detect this effect in the broad population.